Novartis to acquire Tourmaline Bio for

诺华将以14亿美元收购Tourmaline Bio

By Reuters

路透社报道

September 9, 2025

2025年9月9日

BERLIN, Sept 9 (Reuters) - Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday.

⋯ 继续阅读请登录会员 ⋯